Co-chair of Buchanan's FDA Practice Linda Pissott Reig’s recent advisory on the ruling in Amarin Pharma, Inc. v. United States Food & Drug Administration was published in the American Intellectual Property Law Association’s (AIPLA) Food and Drug Committee e-Newsletter.

That ruling is a welcome outcome for pharmaceutical companies that have been clamoring for greater leeway in what they can say in their promotion of prescription drugs to healthcare providers.

“The pharmaceutical industry is now abuzz with excitement about the Amarin v. FDA decision. The excitement is warranted but there are a few caveats that must be kept in mind,” she writes. 

Read the full advisory – “One Small Step for Amarin & One Giant Leap for Pharmaceutical Companies? - Only Time Will Tell” (August 10, 2015) 

Read Linda’s mention in the AIPLA e-Newsletter. 

Read the pickup of Linda's advisory on JD Supra.